Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDI...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 1,012
- Institution
- King's College Hospital
External Links
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.